Neuland Laboratories Limited (NEULANDLAB)

Loading page…

Neuland Laboratories Limited (NEULANDLAB) · mywealthgrid

About

Neuland Laboratories manufactures pharmaceuticals, operating at a scale of ₹641–776 Cr in recent quarterly revenue. With a market cap of ₹29,849.6 Cr, it ranks as a mid-cap player in Indian pharma. The company generates 9–27% net margins and 17–40% operating margins on standalone operations.

Founded: 1984
Face value: ₹10

Market cap

₹27,526 Cr

P/E

55.3×

P/B

14.8×

Dividend yield

0.2%

ROE

21.4%

ROCE

26.1%

Debt / equity

0.1

OPM

28.4%

EPS (TTM)

₹385.9

Book value

₹1,453.1

52-week high

—

52-week low

Key insights

Company research notes and source-linked reviews

Key risks

Valuation stretched: PE of 59.97 leaves minimal margin for error; a single quarter of margin compression like Dec 2025 (17.54% OPM) can trigger sharp re-rating.
Operational volatility: Operating margin swung from 39.54% (Mar 2026) to 17.54% (Dec 2025) to 34.69% (Jun 2026); verify whether this reflects input cost cycles, capacity constraints, or seasonal demand patterns.
Revenue decline from peak: ₹776.25 Cr (Mar 2026) to ₹641.58 Cr (Jun 2026) is a 17% sequential drop; verify whether this is typical seasonality or demand softening.
Pharma sector headwinds (regulatory pricing, generic competition) apply broadly; verify company's exposure to price-controlled products and competitive positioning.

Generated analysis · source review pending

Growth drivers

Peak OPM of 39.54% (Mar 2026) shows operational efficiency; verify if these margin levels are sustainable and whether earnings can grow with flat revenue.
ROE of 21.42% demonstrates capital efficiency and reinvestment capacity; verify capital allocation toward R&D and growth capex.
Revenue recovered from ₹439.71 Cr (Dec 2025) trough to ₹641.58 Cr (Jun 2026); verify whether this reflects structural demand recovery or typical seasonal patterns.
Low debt (D/E 0.1) provides financial flexibility for growth investments; verify company's capex and R&D budget plans.

Generated analysis · source review pending

2,528 historical price candles were omitted because the exchange source has not been verified.

₹21,505.0+0.6%1Y

Quick read

rule-based

Pros

+Strong return on equity of 22.1% (3-yr avg)
+High return on capital employed of 25.5%
+Healthy operating margin of 28.4%
+Profit CAGR of 35.2% over the last 5 years
+Revenue CAGR of 16.6% over the last 5 years
+Comfortable interest coverage of 21.4×

Cons

−Trading at 14.8× book value
−Low dividend payout of 8.7% of profit

Research score

Structured signal from quality, growth, valuation and momentum.

60/100

Business quality: 82
Growth

Revenue & net profit

₹ crore, by fiscal year

RevenuePAT

Margins

% of revenue, by fiscal year

OPMPAT margin

Peers

Comparable companies from the narrowest available industry classification.

Part ofNIFTY SMALLCAP 50 NIFTY SMALLCAP 100 NIFTY SMALLCAP 250 NIFTY MIDSMALLCAP 400 NIFTY 500

Screen this industry Compare top 5 side-by-side

Company	Mkt Cap	EV	Revenue	EBITDA	OPM	PAT	NPM	ROCE	ROE	WC Days
Torrent Pharmaceuticals LimitedTORNTPHARMTORNTPHARM	₹1,61,325 Cr	₹1,76,123 Cr	₹15,723 Cr	₹5,191 Cr	32.6%	₹2,181 Cr	15.3%	14.5%	27.1%	163
Zydus Lifesciences LimitedZYDUSLIFEZYDUSLIFE	₹1,14,284 Cr	₹1,26,053 Cr	₹28,592 Cr	₹8,316 Cr	31.2%	₹4,513 Cr	18.9%	23.4%	19.7%	212
Laurus Labs LimitedLAURUSLABSLAURUSLABS	₹1,07,176 Cr	₹1,09,573 Cr	₹7,270 Cr	₹2,034 Cr	26.1%	₹1,093 Cr	13.1%	21.3%	18.2%	263
Mankind Pharma LimitedMANKINDMANKIND	₹1,04,696 Cr	₹1,11,007 Cr	₹14,738 Cr	₹3,827 Cr	25.3%	₹2,068 Cr	13.6%	14.2%	12.5%	117
Aurobindo Pharma LimitedAUROPHARMAAUROPHARMA	₹97,389 Cr	₹1,05,065 Cr	₹34,935 Cr	₹7,085 Cr	20.3%	₹3,713 Cr	10.4%	14.7%	9.9%	252
Lupin LimitedLUPINLUPIN	₹92,866 Cr	₹98,777 Cr	₹29,967 Cr	₹9,538 Cr	31.5%	₹5,529 Cr	19.2%	34.2%	26.9%	181
Glenmark Pharmaceuticals LimitedGLENMARKGLENMARK	₹65,781 Cr	₹65,781 Cr	₹17,737 Cr	₹4,797 Cr	26.9%	₹1,496 Cr	8%	37.8%	0%	83
Alkem Laboratories LimitedALKEMALKEM	₹62,431 Cr	₹64,055 Cr	₹15,081 Cr	₹3,032 Cr	20.4%	₹2,158 Cr	16%	21.5%	17.8%	152
Biocon LimitedBIOCONBIOCON	₹60,413 Cr	₹75,238 Cr	₹17,321 Cr	₹3,536 Cr	20.4%	₹495 Cr	2.2%	3.9%	1.4%	85
Abbott India LimitedABBOTINDIAABBOTINDIA	₹56,901 Cr	—	₹4,310 Cr	₹921 Cr	27.3%	₹691 Cr	22.4%	44.1%	34.5%	110
Ipca Laboratories LimitedIPCALABIPCALAB	₹49,299 Cr	₹50,003 Cr	₹10,126 Cr	₹2,232 Cr	20.5%	₹1,310 Cr	12.3%	17.8%	15.2%	308
Gland Pharma LimitedGLANDGLAND	₹47,428 Cr	₹47,671 Cr	₹6,725 Cr	₹1,751 Cr	25.3%	₹1,129 Cr	16%	14.8%	10.5%	255

Loading peers…

Financials

Reported profit and loss, balance sheet, cash flow and growth history.

Annual Quarterly

Consolidated Standalone

Consolidated figures · ₹ crore

₹ Cr	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
	763	937	951	1,191	1,559	1,477	2,023
COGS	380	438	422	478	577	588	756
Gross profit	383	498	529	713	981	889	1,267
	281	352	386	441	519	566	693
	102	147	143	272	463	323	575
OPM %	13.4%	15.7%	15%	22.8%	29.7%	21.9%	28.4%
Depreciation	31	40	49	53	60	66	92
Interest	22	18	14	13	14	8	24
	4	16	2	10	13	97	30
Profit before tax	53	105	82	216	401	346	489
Tax	37	25	18	52	101	86	125
Tax %	69.4%	23.5%	22.3%	24.2%	25.3%	24.9%	25.6%
	16	81	64	164	300	260	364
PAT margin %	2.1%	8.6%	6.7%	13.7%	19.3%	17.6%	18%
EPS (₹)	12.6	62.9	49.7	127.5	233.9	202.7	283.7
EPS adjusted (₹)	—	62.5	49.5	126.8	232.6	201.6	282.2
	15.8%	8%	10.1%	7.8%	6%	5.9%	12%
Annual report	Annual report for Mar 2020	Annual report for Mar 2021	Annual report for Mar 2022	Annual report for Mar 2023	Annual report for Mar 2024	Annual report for Mar 2025	Annual report for Mar 2026

₹ Cr	Mar 2016	Mar 2017	Mar 2018	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Equity capital	9	9	9	13	13	13	13	13	13
Reserves	178	180	226	774	828	981	1,270	1,512	1,862
Minority interest	—	311	311	—	—	—	—	—	—
	169	157	181	170	231	122	83	136	197
	168	160	159	368	312	464	467	519	859
Total equity & liabilities	524	817	886	1,325	1,383	1,580	1,833	2,180	2,930
	139	429	436	697	748	738	805	955	1,177
CWIP	40	40	20	17	20	41	46	45	210
Investments	14	15	8	26	24	20	20	109	2
	330	332	422	585	592	781	962	1,071	1,542
Total assets	524	817	886	1,325	1,383	1,580	1,833	2,180	2,930

Loading financials…

Ratios

Annual operating, return, leverage and working-capital ratios.

Consolidated Standalone

Consolidated figures

Ratio	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Margins
Gross margin %	50.2%	53.2%	55.6%	59.9%	63%	60.2%	62.7%
EBITDA margin %	13.4%	15.7%	15%	22.8%	29.7%	21.9%	28.4%
EBIT margin %	9.3%	11.4%	9.8%	18.4%	25.8%	17.5%	23.9%
PAT margin %	2.1%	8.6%	6.7%	13.7%	19.3%	17.6%	18%
Working capital
Receivable days	—	85	90	111	87	78	98
Inventory days	—	206	229	213	222	240	247
Payable days	—	127	101	131	121	157	130
NWC days	—	164	218	193	188	161	214
Leverage
Current ratio	—	1.49	1.6	1.73	2.15	2.45	2.09
Debt to EBITDA	—	1.16	1.62	0.45	0.18	0.42	0.34
Debt to equity	—	0.22	0.27	0.12	0.06	0.09	0.1
Interest coverage	3.5	6.9	7.1	17.5	29.7	33.5	21.4
Asset turnover	—	0.71	0.69	0.75	0.85	0.68	0.69
Return ratios
Return on assets %	—	6.1%	4.6%	10.4%	16.4%	11.9%	12.4%
Return on capital employed %	—	12.9%	9.7%	21.2%	32.6%	17.8%	26.1%
Return on equity %	—	10.3%	7.6%	16.4%	23.4%	17.1%	19.4%

Derived from reported annual statements. ROCE uses EBIT over capital employed (total assets less current liabilities). Day counts average the opening and closing balance; receivables turn on revenue, inventory and payables on cost of goods sold.

Loading ratios…

Shareholding

Quarterly ownership, named holders, insider transactions and disclosed deals.

Quarterly Annual

Every quarter filed · % of equity

Holder (%)	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026	Jun 2026
	35.97%	32.8%	32.74%	32.72%	32.64%	32.68%	32.68%	32.68%	32.64%	32.63%	32.63%	32.62%
	21.57%	22.69%	24.44%	25.72%	26.46%	23.86%	22.11%	21.69%	20.6%	20.9%	20.46%	21.08%
	6.99%	6.03%	6.54%	6.39%	6.38%	9.08%	10.97%	11.57%	13.54%	14.71%	15.84%	16.51%
Government	0%	0%	0%	0%	0%	0%	0%	0%	0.4%	0%	0%	0%
	35.47%	38.48%	36.28%	35.17%	34.52%	34.38%	34.24%	34.06%	32.82%	31.76%	31.07%	29.79%
No. of shareholders	—	—	—	—	—	—	—	—	44,393	46,187	46,304	44,340

Loading shareholding…

F&O

Current futures and options contracts with compact option-chain pages.

Not in the F&O segment

Only about 210 stocks have listed futures and options. Contracts appear here for those, refreshed after each close.

Loading f&o…

Fund holders

Mutual-fund schemes that disclosed a holding in the company.

Portfolio month

Schemes holding

across 14 fund houses

Held by these funds

3.83%

of the company's equity

All mutual funds

12.66%

shareholding pattern, Jun 2026

Portfolios as of

August 2026

compared with July 2026

55 schemes · 14 fund houses

		Shares
Flexi Cap FundNEW	ICICI Prudential Mutual Fund	2.03 L	467.79	1.81%	1.588%	—
Flexi Cap Fund	Bajaj Finserv Mutual Fund	59,718	137.41	1.59%	0.467%	-21,100
(LIVE SCHEMES)	ITI Mutual Fund	26,910	61.92	1.72%	0.21%	-749
TRUSTMF Small Cap Fund	Trust Mutual Fund	21,581	49.66	1.44%	0.169%	+4,487
Small Cap Fund	Bajaj Finserv Mutual Fund	21,556	49.6	1.87%	0.168%	-15,368
Flexi Cap Fund	Axis Mutual Fund	19,136	44.03	0.32%	0.15%	-0
Nifty Smallcap 250 Index Fund	Nippon India Mutual Fund	13,746	31.63	0.9%	0.107%	+169
MF FLEXI CAP FUND	LIC Mutual Fund	10,300	23.7	2.11%	0.08%	-1,250

1–8 of 55

1 / 7

Loading fund holders…

Documents

Annual reports, exchange filings, offer documents, ratings and earnings-call material.

Announcements

Annual reports

Credit ratings

Investor Presentation and earnings call

Aug 2026Transcript AI SummaryPPTREC
May 2026Transcript AI Summary PPT

Documents link to external sources (exchange filings, company investor pages).

Loading documents…

Events

Upcoming dates and the company’s corporate-action history.

Loading events…

Announcements

Latest exchange announcements, filings and downloadable documents.

1 month 3 months 6 months 1 year All

22 announcementsExport CSV

16 Sept 2026, 4:12 pmCompany Update

Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation

Analyst / Investor Meet PDF

15 Sept 2026, 10:27 amCompany Update

Announcement under Regulation 30 (LODR)-Press Release / Media Release

Press Release / Media Release PDF

9 Sept 2026, 6:07 pmCompany Update

Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation

Analyst / Investor Meet PDF

7 Sept 2026, 5:25 pmCompany Update

Disclosure Under Regulation 30 Of SEBI Listing Regulations

General PDF

25 Aug 2026, 8:39 pmCompany Update

Announcement under Regulation 30 (LODR)-Credit Rating

Credit Rating PDF

23 Aug 2026, 8:03 pmCompany Update

Announcement under Regulation 30 (LODR)-Newspaper Publication

Newspaper Publication PDF

17 Aug 2026, 2:03 pmInsider Trading / SAST

Disclosures under Reg. 29(2) of SEBI (SAST) Regulations, 2011

Disclosures under Reg. 29(2) of SEBI (SAST) Regulations, 2011 PDF

14 Aug 2026, 6:52 pmCompany Update

Intimation Regarding Completion Of US FDA Inspection

General PDF

Date	Category	Subject	Filing
16 Sept 2026, 4:12 pm	Company Update Analyst / Investor Meet	Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation	PDF
15 Sept 2026, 10:27 am	Company Update Press Release / Media Release	Announcement under Regulation 30 (LODR)-Press Release / Media Release

Loading announcements…

Ratio	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Margins
Gross margin %	50.2%	53.2%	55.6%	59.9%	63%	60.2%	62.7%
EBITDA margin %	13.4%	15.7%	15%	22.8%	29.7%	21.9%	28.4%
EBIT margin %	9.3%	11.4%	9.8%	18.4%	25.8%	17.5%	23.9%
PAT margin %	2.1%	8.6%	6.7%	13.7%	19.3%	17.6%	18%
Working capital
Receivable days	—	85	90	111	87	78	98
Inventory days	—	206	229	213	222	240	247
Payable days	—	127	101	131	121	157	130
NWC days	—	164	218	193	188	161	214
Leverage
Current ratio	—	1.49	1.6	1.73	2.15	2.45	2.09
Debt to EBITDA	—	1.16	1.62	0.45	0.18	0.42	0.34
Debt to equity	—	0.22	0.27	0.12	0.06	0.09	0.1
Interest coverage	3.5	6.9	7.1	17.5	29.7	33.5	21.4
Asset turnover	—	0.71	0.69	0.75	0.85	0.68	0.69
Return ratios
Return on assets %	—	6.1%	4.6%	10.4%	16.4%	11.9%	12.4%
Return on capital employed %	—	12.9%	9.7%	21.2%	32.6%	17.8%	26.1%
Return on equity %	—	10.3%	7.6%	16.4%	23.4%	17.1%	19.4%

1 disclosure

Person	Deal	Shares	Value	Holding	Filed
Mr. Gannabathula Venkata Krishna Rama RaoPromoters	BuyGift	9,000	₹0	0.00% → 0.01%	24 Sept 20257(2)

Disclosed under SEBI’s insider-trading regulations, which require a filing only above ₹10 lakh in a quarter — smaller dealings are in no disclosure. Holdings are the filer’s own percentages, not recomputed.

16 deals · 6 Aug 2021 – 6 Aug 2026

Date	Client	Type	Venue	Side	Quantity	Price	Value
6 Aug 2026	HDFC MUTUAL FUND	Bulk	NSE	Buy	64,547	₹21,585.00	₹139.32 Cr
5 Sept 2025	AIRAVAT CAPITAL TRUST II	Block	NSE	Buy	8,896	₹14,612.00	₹13.00 Cr
5 Sept 2025	AIRAVAT CAPITAL TRUST	Block	NSE	Sell	8,896	₹14,612.00	₹13.00 Cr
12 Dec 2024	SMALLCAP WORLD FUND INC	Bulk	NSE	Sell	4,84,434	₹15,618.16	₹756.60 Cr
26 Jun 2024	SMALLCAP WORLD FUND INC	Block	BSE	Buy	1,30,000	₹7,400.00	₹96.20 Cr
26 Jun 2024	MALABAR INDIA FUND LIMITED	Block	BSE	Sell	1,30,000	₹7,400.00	₹96.20 Cr
26 Jun 2024	SMALLCAP WORLD FUND INC	Bulk	BSE	Buy	1,30,000	₹7,400.00	₹96.20 Cr
26 Jun 2024	MALABAR INDIA FUND LIMITED	Bulk	BSE	Sell	1,30,000	₹7,400.00	₹96.20 Cr
8 Dec 2023	RAMAMOHAN RAO DAVULURI	Bulk	BSE	Sell	4,00,000	₹5,012.45	₹200.50 Cr
31 Aug 2023	BNP PARIBAS ARBITRAGE	Bulk	NSE	Sell	64,893	₹3,871.31	₹25.12 Cr

1–10 of 16

1 / 2

Bulk deals are a client trading over 0.5% of the equity in a session, aggregated across their trades; block deals are single negotiated trades in the exchange’s block window. Each is reported by the exchange it was crossed on, so NSE and BSE rows are separate trades rather than the same trade twice.

₹ Cr	Mar 2016	Mar 2017	Mar 2018	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
	45	39	11	189	59	237	261	317	347
	-20	-42	-116	-84	-94	-62	-150	-298	-424
	-24	-0	105	-114	38	-136	-69	25	21
Net cash flow	1	-4	-0	-9	3	40	42	44	-56
Free cash flow	26	-2	-122	84	-37	172	120	111	-43
CFO / Operating profit %	—	—	—	129%	41.1%	87.3%	56.5%	98.2%	60.3%

Neuland Laboratories Limited

About

Key insights

Key risks

Growth drivers

Quick read

Pros

Cons

Research score

Revenue & net profit

Margins

Peers

Financials

Ratios

Shareholding

F&O

Not in the F&O segment

Fund holders

Documents

Announcements

Annual reports

Credit ratings

Investor Presentation and earnings call

Events

Announcements

Not in the F&O segment

17

1

Announcements

Annual reports

Credit ratings

Investor Presentation and earnings call

Compounded sales growth

Compounded profit growth

Return on equity

Neuland Laboratories Limited

About

Key insights

Key risks

Growth drivers

Quick read

Pros

Cons

Research score

Revenue & net profit

Margins

Peers

Financials

Profit & loss

Balance sheet

Ratios

Ratio timeline

Shareholding

Quarterly record

F&O

Not in the F&O segment

Fund holders

Documents

Announcements

Annual reports

Credit ratings

Investor Presentation and earnings call

Events

Announcements

Ratio timeline

Not in the F&O segment

Quarterly record

Dividends17

Board meetings1

Insider dealing

Bulk & block deals

Board and management

Announcements

Annual reports

Credit ratings

Investor Presentation and earnings call

Profit & loss

Balance sheet

Cash flow

Compounded returns

Compounded sales growth

Compounded profit growth

Return on equity

17

1